Latest Altimmune News & Updates

See the latest news and media coverage for Altimmune. We track all announcements, press releases, and industry mentions in real time, all in one place.

Altimmune

Clinical stage biopharmaceutical company developing peptide-based therapeutics

altimmune.com

Headquarters: Gaithersburg, United States
Founded year: 1997
Company type: Public company
Number of employees: 10–90
Industry: Pharmaceuticals

Last updated Today

Latest news about Altimmune

In short: Altimmune advanced its lead asset pemvidutide through positive Phase 2b MASH trials and secured significant funding for Phase 3 studies.

Company announcements

June 2 Altimmune

Altimmune announces positive pemvidutide data at EASL 2026

New analyses show concurrent improvements in NITs and qFibrosis regression at 24 weeks.

May 13 Altimmune

Altimmune will present pemvidutide MASH data at EASL Congress

The 48-week IMPACT data is highlighted in an oral presentation and multiple posters, including a late-breaker on fibrosis regression.

May 6 Altimmune

Altimmune announces Q1 2026 financial results and business update

Cash position strengthened to $535M after April offering; Phase 3 MASH trial to start H2 2026; AUD topline data expected Q3 2026.

April 22 Altimmune

Altimmune announces proposed public offering of securities

The offering will fund Phase 3 MASH trial and working capital.

Media coverage

May 6 Seeking Alpha

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and...

April 27 The Business Journals

Altimmune secures $225M to test GLP-1 in liver disease, eyes first commercial product launch - Washington Business Journal

Altimmune raises $225 million to fund a phase 3 trial of pemvidutide, a GLP-1 therapy for liver disease, under new CEO Jerry Durso.

April 22 The Manila Times

Altimmune Announces Proposed Underwritten Public Offering of Securities

GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE)-- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today ...

March 6 Stock Titan

Altimmune 2025 results, pemvidutide and cash runway | ALT Annual Report (10-K)

Altimmune’s 2025 10-K shows a $88.1M net loss, strong pemvidutide Phase 2b MASH data, and $273.5M in year-end liquidity, with management expecting at least 12...

Never miss news about Altimmune

Track Altimmune and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Altimmune competitors & trending companies

Browse news for competitors to Altimmune and other trending companies.